Studies showing recent advances in the treatment of tricuspid valve disease.
| Study, year | Study design | Place of study | Sample size (n) | Intervention | outcome | Follow-up duration | |||
|---|---|---|---|---|---|---|---|---|---|
| Sample size (n) | Name of intervention | Previous surgery | Primary | secondary | |||||
| Alnajar et al., 2024 [43] | Retrospective analysis | U.S. | 51 | Replacement(n = 33)Repair(n = 18) | Mini-TVS | Median sternotomy cardiac surgery | In-hospital mortality and overall survival | Complications like stroke, MI, transfusion, and arrhythmias | 17 months |
| Arafat et al., 2024 [44] | Retrospective cohort study | NA | 617 | Isolated TV(n = 63)Concomitant TV(n = 554) | Isolated and concomitant TVS | NA | Overall operative mortality rate, rates of postoperative renal failure, and need for ventilation more than 24 h after surgery | Late outcomes and heart failure rehospitalization | 2009 to 2020 |
| Shimoda et al., 2025 [45] | Medicare fee-for-service 100%, sample inpatient file provided by the Centers for Medicare & Medicaid Services | U.S. | 1,501 | Replacement(n = 610)Repair(n = 891) | Isolated tricuspid replacement versus repair | NA | Early-term (up to 3 years) all-cause mortality | Early-term MACE and heart failure hospitalizations | 18.7 months |
| Altrabsheh et al., 2025 [46] | Retrospective study | U.S. | 298 | 298 | ITVS | Previous surgical intervention Hx | Operative mortality, survival | Late death and 5-year survival | 5.4 years |
| Hahn et al., 2025 [37] | International multicenter randomized controlled trial | 45 centers in the U.S. and Germany | 400 | Transcatheter tricuspid valve replacement(n = 267)Control(n = 133) | Valve replacement | NA | Death from any cause, implantation of a right ventricular assist device or heart transplantation, post-index tricuspid-valve intervention, hospitalization for heart failure, or an improvement of at least 10 points (KCCQ-OS) | NA | 5 years |
ITVS: isolated tricuspid valve surgery; KCCQ-OS: Kansas City Cardiomyopathy Questionnaire-Overall Summary; MACE: major adverse cardiovascular events; MI: myocardial infarction.